{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:31:01Z","timestamp":1786681861005,"version":"build-2736575974"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hashimoto\u2019s thyroiditis (HT) and papillary thyroid carcinoma (PTC) frequently coexist, but the precise impact of HT on PTC invasiveness \u2014 particularly across the strict American Joint Committee on Cancer (AJCC) 8th-edition extrathyroidal extension (ETE) categories \u2014 remains incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 266 consecutive patients with histopathologically confirmed PTC (69 with concurrent HT; 197 without) who underwent thyroidectomy with routine prophylactic central neck dissection at our institution between March 2020 and December 2022. ETE was stratified per strict AJCC 8th-edition criteria into three tiers: No ETE (including pure thyroid capsule invasion), Microscopic ETE (perithyroidal fat invasion), and Gross ETE (T3b strap-muscle or T4 organ invasion). The primary multivariable models adjusted for age, sex, tumor diameter, and multifocality but deliberately excluded BRAF V600E mutation (treated as a mediator on the HT\u2192aggressiveness pathway) to avoid overadjustment bias; secondary models including BRAF are also presented. Sensitivity analyses for nodal metrics included binary logistic regression for any CLNM and negative binomial regression for positive node count with log(nodal yield) offset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Under strict AJCC 8 reclassification, gross ETE was observed in 10.7% of HT(\u2212) versus 4.3% of HT(+) patients (adjusted OR\u00a0=\u00a00.21, 95% CI 0.06\u20130.81, P\u00a0=\u00a00.024). HT was an independent protective factor for ETE severity in ordinal regression (adjusted OR\u00a0=\u00a00.41, 95% CI 0.19\u20130.88, P\u00a0=\u00a00.023) and for BRAF V600E mutation (adjusted OR\u00a0=\u00a00.47, 95% CI 0.25\u20130.88, P\u00a0=\u00a00.018). High CLNM ratio (\u22650.4) was less frequent in HT(+) (adjusted OR\u00a0=\u00a00.47, 95% CI 0.23\u20130.93, P\u00a0=\u00a00.029), and yield-adjusted negative binomial regression confirmed HT independently reduced the positive node count (IRR\u00a0=\u00a00.56, 95% CI 0.40\u20130.78, P &amp;lt; 0.001). The proportion with any CLNM did not differ between groups (62.9% vs. 55.1%, P\u00a0=\u00a00.313), nor did Ki-67 \u22655% (27.4% vs. 26.9%, P\u00a0=\u00a01.000). The proportional-odds assumption for ordinal regression was supported (Brant-type tests, all P &amp;gt; 0.30). Exploratory analyses across TPOAb strata suggested a stepwise gradient with BRAF V600E (Ptrend = 0.020) but were limited by very small subgroup sizes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this Chinese single-center cohort, HT was independently associated with a less aggressive PTC phenotype \u2014 reduced gross ETE, lower BRAF V600E mutation, and reduced nodal metastatic burden \u2014 after applying strict AJCC 8 criteria and a causal-inference-informed analytic strategy. These observations strengthen the biological hypothesis that HT modulates PTC behavior, but require prospective multi-center validation with recurrence and survival endpoints before any clinical management changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1897756","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:23:24Z","timestamp":1786681404000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lower invasiveness of papillary thyroid carcinoma associated with Hashimoto\u2019s thyroiditis: evidence from AJCC 8th-edition stratification and a dose\u2013response relationship with autoantibody titers"],"prefix":"10.3389","volume":"17","author":[{"given":"SiCong","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Thyroid Vascular Surgery, Fujian Province Second People\u2019s Hospital, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[{"name":"Ultrasound Department, Fujian Province Second People\u2019s Hospital, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Vascular Surgery, Fujian Province Second People\u2019s Hospital, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Thyroid Vascular Surgery, Fujian Province Second People\u2019s Hospital, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cao","sequence":"additional","affiliation":[{"name":"Ultrasound Department, Fujian Province Second People\u2019s Hospital, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"key":"B3","article-title":"Papillary thyroid carcinoma","volume-title":"StatPearls [Internet]","author":"Limaiem","year":"2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.007","article-title":"Hashimoto thyroiditis: clinical and diagnostic criteria","volume":"13","author":"Caturegli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102649","article-title":"Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential Malignant transformation","volume":"19","author":"Ralli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000468928","article-title":"Thyroid autoimmunity and thyroid cancer: review focused on cytological studies","volume":"6","author":"Boi","year":"2017","journal-title":"Eur Thyroid J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269995","article-title":"Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis","volume":"17","author":"Tang","year":"2022","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1273498","article-title":"Prevalence and impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto's thyroiditis: a systematic review with meta-analysis","volume":"14","author":"Janicki","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-011-9164-9","article-title":"Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence","volume":"22","author":"Huang","year":"2011","journal-title":"Endocr Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17842-4","article-title":"Hashimoto's thyroiditis shows sex- and age-dependent inverse associations with papillary thyroid carcinoma progression: A propensity score-matched analysis of 6963 surgical cases","volume":"32","author":"Ma","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1695508","article-title":"Hashimoto's thyroiditis reduces central lymph node metastasis risk in papillary thyroid microcarcinoma: an integrated meta-analysis","volume":"16","author":"Zhong","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): What changed and why","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"key":"B13","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2017.01.046","article-title":"ACR thyroid imaging, reporting and data system (TI-RADS): White paper of the ACR TI-RADS committee","volume":"14","author":"Tessler","year":"2017","journal-title":"J Am Coll Radiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10082051","article-title":"Hashimoto's thyroiditis minimizes lymph node metastasis in BRAF mutant papillary thyroid carcinomas","volume":"10","author":"Issa","year":"2022","journal-title":"Biomedicines"},{"key":"B18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41420-024-02157-2","article-title":"High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104646","article-title":"The current understanding of the molecular pathogenesis of papillary thyroid cancer","volume":"26","author":"Carnazza","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1530\/ERC-13-0431","article-title":"The role of the inflammatory microenvironment in thyroid carcinogenesis","volume":"21","author":"Cunha","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2564","article-title":"Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer","volume":"95","author":"French","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1897756\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:23:25Z","timestamp":1786681405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1897756\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":25,"alternative-id":["10.3389\/fendo.2026.1897756"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1897756","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1897756"}}